智翔金泰签订唯康度塔单抗和斯乐韦米单抗注射液商业化合作，将获得首付款、里程碑付款约5.1亿元

Core Insights - Zhixiang Jintai (688443) announced a collaboration agreement with Tibet Kangzhe Pharmaceutical Development Co., Ltd. and RXILIENT MEDICAL PTE. LTD. for the exclusive rights to two monoclonal antibody injections [1] Group 1: Collaboration Details - The agreement includes an upfront payment and milestone payments totaling approximately 510 million yuan [1] - Zhixiang Jintai will provide commercialization and promotional services for the products [1] - Tibet Kangzhe will hold exclusive commercialization rights for the two products in mainland China [1] - RXILIENT will obtain exclusive licensing rights for the products in the Asia-Pacific region, as well as the Middle East and North Africa [1]